gorodenkoff/iStock via Getty Images
- Coscience Biopharma (Nasdaq:CSCI), on Monday, provided an update to the company and It reiterated pipeline priorities. The company said it has streamlined efficiencies and taken cost-cutting measures to improve operations and development path forward.
- Avenanthramide tablets in development as an anti-inflammatory: Phase
https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1293773576/image_1293773576.jpg?io=getty-c-w750
Source link